Skip to main content
. 2016 Jan 6;6:18633. doi: 10.1038/srep18633

Figure 2. In vivo VIP treatment increases the number of viable implantation sites and improves the asymmetric distribution.

Figure 2

CBA/J × DBA/2 females were treated in vivo with VIP (2 nmol/mouse) or PBS i.p. at day 6.5 of gestation. At d8.5 females were sacrificed and (A) number of viable implantation sites and (B) the asymmetric distribution of implanted embryos were evaluated as described in Material and Methods. Values are media ± S.E. of viable sites counted in 8 mice (control group), 18 mice (CBAxDBA, PBS group) and 15 mice (CBAxDBA, VIP group).